-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Crohn's disease (CD) is an inflammatory bowel disease (IBD) characterized by transmural inflammation in any area of the gastrointestinal trac.
This trial pooled analysis of 299 CD patients from 4 clinical trial.
Adalimumab (17/61 [29%], [OR]: 79, 95% [CI]: 77–195, P= 004) and infliximab (39/141 [27%], aOR: 59, 95% CI: 48–122, P = 008) had a higher incidence of EH at 1 yea.
This study initially demonstrated that TNF-α antagonists (adalimumab and infliximab) were generally superior to vedolizumab and ustekinumab in achieving 1-year EH in patients with moderate-to-severe C.
Original source:
Narula, Neera.